ELV·Elevance Health, Inc.

Elevance Health, Inc. is a prominent U.S. health benefits company offering a wide array of health plans and services through four key segments, serving individuals, employer groups, and government programs. Beyond traditional insurance, its offerings include pharmacy services, specialty insurance, and healthcare services like care management and virtual care, supported by its HealthOS platform and delivered under well-known brands. The company's recent earnings performance presents a mixed picture with an anticipated downturn in the upcoming Q1 2026 report. For Q4 2025, Elevance reported EPS of $3.33, exceeding the estimate of $3.13, and revenue of $49.31 billion against an estimate of $50.31 billion, indicating an EPS beat but a revenue miss. Prior quarters showed stronger beats, with Q1 2025 EPS at $11.97 beating the $11.48 estimate, Q2 2025 EPS at $8.84 beating the $8.96 estimate (a slight miss), and Q3 2025 EPS at $6.03 beating the $4.94 estimate. This suggests a recent deceleration in performance compared to earlier periods. Historically, Elevance has demonstrated a pattern of exceeding analyst estimates, particularly in EPS, though revenue performance has been more variable. Recent news indicates that analysts are forecasting a year-over-year decline in both EPS and revenue for the upcoming Q1 2026 report, with downward revisions for full-year 2026 estimates, suggesting potential headwinds. Baird has also lowered its price target to $317 from $340 while maintaining a Neutral rating. Investors should watch for management's commentary on the drivers of the anticipated weakness in health benefits and strategies to mitigate these factors, as well as any signs of stabilization or improvement in the outlook for the remainder of the year, especially in light of the recent downward estimate revisions and tempered analyst sentiment.